复方淫羊藿胶囊质量标准的研究

目的建立复方淫羊藿胶囊的质量控制方法。方法用薄层色谱法对复方淫羊藿胶囊制剂中的淫羊藿、女贞子进行定性鉴别,HPLC法测定淫羊藿苷的含量。结果鉴别方法专属性好,测定淫羊藿苷的线性范围为4.096μg·mL-1～24.576μg·mL-1,r=0.9995,平均加样回收率99.43%,RSD=0.62%(n=6)。结论方法专属性好,稳定,可用于复方淫羊藿胶囊的质量控制。     

淫黄颗粒质量控制方法研究

目的建立淫黄颗粒的质量控制方法。方法采用薄层色谱法对淫黄颗粒中淫羊藿、黄芪进行定性鉴别;采用高效液相色谱法对其中淫羊藿苷的含量进行测定。结果在同一薄层板上可同时对淫羊藿、黄芪进行定性检测;淫羊藿苷进样量在0.12504~0.75024μg范围内线性关系良好(r=0.9999),平均加样回收率为97.20%(RSD=1.38%)。结论本方法简便、准确、重现性好,适用于淫黄颗粒的质量控制。     

抗骨增生片的质量标准研究

目的 建立抗骨增生片的质量标准.方法 采用TCL法对肉苁蓉、淫羊藿进行定性鉴别,用HPLC法测定抗骨增生片中淫羊藿苷的含量.结果在薄层色谱中均能检出肉苁蓉、淫羊藿,淫羊藿苷在0.111～1.110 μg范围内呈良好的线性关系(r=0.9999),平均回收率为100.2%,RSD为0.7%(n=9).结论 该方法简便快速,结果准确,重现性好,可作为该制剂的质量控制方法.     

龟鹿补肾丸的质量控制

目的：建立龟鹿补肾丸的定性鉴别和定量测定方法。方法：采用TLC法对龟鹿补肾丸进行定性鉴别：用HPLC法测定该制荆中淫羊藿苷的含量。结果：薄层色谱法可鉴别出该制剂中的陈皮、黄芪、酸枣仁和淫羊藿。HPLC法含量测定中,淫羊藿苷的浓度在1-30μg·ml^-1范围内呈良好线性,样品的平均加样回收率为99．87％,RSD为2．5％。结论：建立的定性和定量方法均具有专属性好、准确和可靠的特点,可作为该制剂的质量控制方法。     

更年乐水丸的质量标准研究

目的建立更年乐水丸的质量控制方法。方法采用薄层色谱法对女贞子、淫羊藿进行鉴别,应用高效液相色谱法测定淫羊藿中的淫羊藿苷含量。结果 TLC鉴别女贞子、淫羊藿方法简便易行,斑点清晰,专属性强;高效液相色谱法测定淫羊藿苷含量,平均回收率为94.17%,RSD为2.2%(n=6)。结论该方法合理,简便,结果准确,可用于更年乐水丸的质量控制。     

延年乐口服液中淫羊藿苷的鉴别和含量测定

目的:建立延年乐口服液中淫羊藿的鉴别和含量测定的标准,以增加对制剂主药的质量控制.方法:以淫羊藿苷作对照品,采用薄层色谱法做鉴别;高效液相色谱法做含量测定.结果:检出供试品淫羊藿苷清晰的斑点;含量测定淫羊藿苷浓度18.968～113.808μg/ml范围内线性关系良好(r=1.000),平均回收率为97.45%,RSD为1.70%.结论:本法测定淫羊藿苷简便、专属性强、准确、重现性好,可用于延年乐口服液淫羊藿苷鉴别和含量测定.     

阳春片的质量标准研究

目的建立阳春片质量控制方法。方法用薄层色谱法对该药中的淫羊藿、山茱萸进行定性鉴别;采用高效液相色谱法测定淫羊藿苷含量。结果薄层色谱鉴别斑点清晰,阴性对照无干扰,淫羊藿苷在20～1000ng内线性关系良好（r=0.9999）,平均回收率为99.12%,RSD为1.67%（n=6）。结论该方法操作简便,结果稳定可靠,专属性强,可为该制剂的质量控制提供参考。     

阳春片的质量标准研究

目的建立阳春片质量控制方法。方法用薄层色谱法对该药中的淫羊藿、山茱萸进行定性鉴别;采用高效液相色谱法测定淫羊藿苷含量。结果薄层色谱鉴别斑点清晰,阴性对照无干扰,淫羊藿苷在20～1000ng内线性关系良好(r=0.9999),平均回收率为99.12%,RSD为1.67%(n=6)。结论该方法操作简便,结果稳定可靠,专属性强,可为该制剂的质量控制提供参考。     

九阳参麒方质量标准研究

目的建立九阳参麒方的质量控制标准。方法采用薄层色谱法对制剂中枸杞子和人参进行薄层定性鉴别;采用反相高效液相色谱法测定淫羊藿中淫羊藿苷的含量。结果薄层定性鉴别专属性强、重现性好;淫羊藿苷在0.03348～0.3348μg范围内呈良好线性关系(r=0.9997),平均回收率为101.4%,RSD为2.03%。结论建立的薄层定性鉴别方法与含量测定方法可靠,可有效地控制该制剂的质量。     

强脊炎丸质量标准研究

目的：建立强脊炎丸的质量标准。方法：采用薄层色谱法对强脊炎丸中的淫羊藿、何首乌、党参、当归、川芎、白芍等六味主要中药进行了鉴别,以高效液相色谱法对其主药淫羊藿中的淫羊藿苷进行含量测定。结果：定性鉴别分离度好,专属性强;淫羊藿苷的含量测定线性范围为0．0944—0．9440μg（r=0．9998）,平均回收率为100．28％,RSD=1．92％。结论：所建立之方法可靠、准确、专属性强,可有效控制强脊炎丸的质量。     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.